An­a­lysts track a pay­er re­volt against Sarep­ta’s con­tro­ver­sial Duchenne drug

When the FDA’s Janet Wood­cock pushed through a con­tro­ver­sial ap­proval for Sarep­ta’s Ex­ondys 51 for Duchenne mus­cu­lar dy­s­tro­phy in Sep­tem­ber, she cre­at­ed a test …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.